TUSC2 and neoplasm: Initiated by discovery of a truncated form of FUS1/TUSC2 (deletion of C-terminal 83-110 aa) in tumor cells, Lin et al. showed that the FUS1/TUSC2 81-96 aa C-terminal peptide linked with stearate inhibits c-Abl activity and facilitates its degradation.